Aquavit Pharmaceuticals AG is a Swiss biotech and pharmaceutical enterprise — developing drugs, biologics and devices, and uniting that science with a deep intellectual-property base, proprietary artificial intelligence and disciplined financial strategy.
Science personalized. Healthcare modernized.
At its core, Aquavit is a biotechnology and pharmaceutical company. Around that core — its science, its assets and its intellectual property — it has built the full arc of modern medicine.
Aquavit Pharmaceuticals AG develops drugs, biologics and devices, and carries them across the full arc of modern medicine — from intellectual property and global market access to asset transactions — all backed by disciplined financial strategy.
That core is real and active: a deep base of intellectual property — spanning biologics, pharmaceutical and device technologies — from which the company is now advancing specific assets through full development. Artificial intelligence and capital give that work force and reach.
Artificial intelligence runs through all of it, and capital gives it force. Together they make the enterprise greater than the sum of its parts, and make Aquavit a partner of consequence rather than a point solution.
What separates medicine from the people and places that need it is rarely scarcity — it is friction. Aquavit's proprietary engines are built to remove it, aligning regulation, distribution and capital so that access flows in every direction: patients to medicine, products to markets, capital to opportunity. When the market moves efficiently, every participant gains.
Real-time, jurisdiction-specific regulatory clearance and reimbursement intelligence — the defensible core that lets a specialty asset move cleanly through the differing rules of every market, at scale.
Orchestrates premium-product distribution and demand across territories — expanding reach and supplier volume without channel conflict, so commercial growth compounds market by market.
AI-accelerated pathways from candidate to clinic to approval.
Precision drug-delivery and microchannel device engineering.
Big-data and RWE analysis that informs access and outcomes.
Intelligent stewardship of IP and exclusivity worldwide.
Acquiring, licensing and structuring breakthrough assets.
Capital structures that fund growth and compound value.
Aquavit Pharmaceuticals AG is the home to which the intellectual property of the wider Aquavit franchise is being brought together — a single, deepening foundation rather than a scattering of rights.
Precision delivery and microchannel platforms, advanced in collaboration with Swiss engineering partners.
Proprietary drug, biologic and delivery technologies refined across years of development.
A heritage of big-data and analytics patents, now consolidated into the company's proprietary AI engines.
Dermatological and aesthetic science, and the patents that protect it.
Held in one place, these rights do more than protect — they compound. Each acquisition, collaboration and discovery adds to a foundation that quietly underwrites everything the company will build next.
The hardest path in medicine runs from a licensed asset to a patient in another country, through regulators, payers, distributors and standards that differ everywhere. It also takes capital. This is precisely the problem our model was built to solve.
The same proprietary engines and financial discipline that move Aquavit's own assets are built to power the Jet Platform — our latest venture, creating a unified commerce, capital and intelligence layer for global specialty medicine, a market that has never had one. Aquavit's AI, IP and pharmaceutical substance are the foundation it is built on.
“Medicine is entering a new era — one where science, intelligence and capital move as one. We are building it from Switzerland, where a heritage of precision and trust meets the technology of a new century. This is the ground from which we intend to lead.”
She is a trained pharmacoeconomist from Yale School of Medicine. Prior to Aquavit, she led portfolios at several Fortune 100 companies in pharmaceuticals, biologics and devices, and served at the U.S. Food and Drug Administration. Today, she holds leadership roles across the Aquavit Group of Companies globally.
